Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim's Phase II Agent Could Be The First Second-Wave Protease Inhibitor For Hep C

This article was originally published in The Pink Sheet Daily

Executive Summary

BI's '355 has impressive response rates in early studies, but jaundice is a concern.
Advertisement

Related Content

Boehringer’s Next Gen Protease Inhibitor Potent In Tough-to-Treat Hep C Patients
Vertex's Telaprevir Works In Twice Daily Dose; Response-Guided Therapy Cuts Down Drop-Outs
INFORM-1 Data Show Potential Efficacy And Safety Of Roche HCV Combo
INFORM-1 Data Show Potential Efficacy And Safety Of Roche HCV Combo
Anemia Not A “Deal Breaker” For Boceprevir – SPRINT-1 Study Investigator
Vertex And Schering Hold Hep C Lead, But Others Look To Deal Themselves In

Topics

Advertisement
UsernamePublicRestriction

Register

PS068826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel